Translational Development Acquisition (TDAC) Net Income towards Common Stockholders (2024 - 2026)

Translational Development Acquisition has reported Net Income towards Common Stockholders for 3 years, with the latest figure at $283351.0 in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 75.74% year-over-year to $283351.0; the trailing twelve-month figure through Mar 2026 stood at -$464884.0 (down 139.97% YoY), and the FY2025 full-year result was $1.4 million, up 28824.61% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $283351.0, up from -$2.4 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $1.3 million in Q3 2025, with the low at -$2.4 million in Q4 2025.
• Historically, Net Income towards Common Stockholders has averaged $87272.8 across 3 years, with a median of $170805.0 in 2024.
• The largest YoY upside for Net Income towards Common Stockholders was 20581.9% in 2025 against a maximum downside of 4220.46% in 2025.
• Translational Development Acquisition's Net Income towards Common Stockholders stood at $58259.0 in 2024, then tumbled by 4220.46% to -$2.4 million in 2025, then surged by 111.8% to $283351.0 in 2026.
• The last three Net Income towards Common Stockholders figures came in at $283351.0 (Q1 2026), -$2.4 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.